NCT02505776View on ClinicalTrials.gov

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

CompletedOBSERVATIONAL
Enrollment

1,699

Participants

Timeline

Start Date

December 8, 2014

Primary Completion Date

May 21, 2018

Study Completion Date

May 21, 2018

Conditions
Eyelash Hypotrichosis
Interventions
DRUG

Bimatoprost cutaneous solution 0.03%

Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.

Trial Locations (1)

Unknown

Tokyo

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY